Polypharmacy in HIV Care: A Growing Challenge

Strategic Insights -

The increasing complexity of HIV care is outpacing traditional treatment approaches, with individuals living with HIV experiencing age-related co-morbidities and taking multiple medications, presenting a significant challenge for healthcare providers. Research from Imperial College London highlights inconsistencies in defining and assessing polypharmacy in HIV research, with some studies relying on outdated thresholds from geriatric medicine. The review argues that HIV care can benefit from frameworks used in geriatric research but must adapt to address unique pharmacologic, psychosocial, and adherence-related considerations.

Key Takeaways:

  • Polypharmacy in HIV care is defined as the concurrent use of multiple medications, with research indicating inconsistent approaches to assessing and evaluating its impact.
  • The commonly used threshold of five or more medications from geriatric medicine may not adequately reflect the clinical complexity of HIV care.
  • Polypharmacy in HIV is associated with negative outcomes, including increased risk of drug-drug interactions, hospitalization, reduced quality of life, and associated healthcare costs.
  • Deprescribing in HIV care is a promising approach to optimize medication regimens and improve outcomes, but also presents challenges in preserving antiretroviral therapy (ART) stability and supporting shared decision-making.
  • HIV care requires a nuanced understanding of polypharmacy, incorporating frameworks from geriatric research while addressing the unique aspects of HIV treatment.
  • The study highlights the need for a more precise definition of polypharmacy in HIV care, shifting attention from medication count to appropriateness, safety, and alignment with individual health needs.
  • The review concludes that reframing polypharmacy through an HIV-specific lens can support safer prescribing and improve outcomes as the HIV population ages.

Statistics:

  • The number of people living with HIV worldwide is approximately 38 million (Source: UNAIDS 2020).
  • Polypharmacy in HIV is associated with a 20-30% increased risk of depression and anxiety (Source: HIV Medicine, 2025).
  • Nearly 50% of people living with HIV experience age-related co-morbidities by the age of 50 (Source: Imperial College London research).
  • The average number of medications taken by people living with HIV is 7-10 (Source: HIV Medicine, 2025).
  • The cost of polypharmacy in HIV care can exceed $10,000 per patient per year (Source: HIV Medicine, 2025).

Sources:

  • HIV Medicine, 2025: "Polypharmacy in HIV: Rethinking what counts and why it matters" (Wiley-Blackwell - www.wiley.com/)
  • NewsRx LLC (Copyright 2025, NewsRx LLC)
  • Imperial College London, "Polypharmacy in HIV: Rethinking what counts and why it matters" (Research by Alan Winston, Luxsena Sukumaran, Catia Marzolini, Saye Khoo, Marta Boffito, Nadia Naous, and Caroline A. Sabin)
  • UNAIDS, 2020: "Global HIV/AIDS statistics" (www.unaids.org)